
Conference Abstracts & Journals
ALTB-168, an Immune Checkpoint Enhancer (ICE) targeting P-selectin glycoprotein-1 (PSGL-1), is effective in treating T-cell mediated inflammatory diseases
ALTB 268, a Tetravalent Anti PSGL 1 Antibody Derived From ALTB 168, Shows Enhanced Potency in Treating T cell Mediated Inflammatory Diseases Allowing for Subcutaneous Administration
A novel AI Tool is accurate at interpreting histology and detects response to Neihulizumabtherapy in patients with moderate to severe ulcerative colitis: Proof of Concept
A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, AN ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATE TO SEVERE ACTIVE, ANTI-TNF AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS
NEIHULIZUMAB (ALTB-168) IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST-DISEASE (SR-aGVHD)or TREATMENT-REFRACTORY ACUTE GRAFT-VERSUS-HOST-DISEASE (TR-aGVHD
Checkpoint Regulator, Neihulizumab, as a Novel Therapy for Immunological Diseases
Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study
NEIHULIZUMAB (ABGN-168H) IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFTVERSUS- HOST-DISEASE (SR-AGVHD): PRELIMINARY RESULTS OF A PHASE I STUDY
Phase II open label, single arm, multiple dose study of Neihulizumab , an anti CD162 (PSGL 1) antibody, in patients with moderate to severe active, anti TNFα and/or anti integrin refractory ulcerative colitis
Phase Ia,first-in-human study of AbGn-107,a novel antibody-drug conjugate(ADC),in patients with gastric,colorectal,pancreatic,or biliary cancers
A novel apoptosis-inducing anti-PSGL-1 antibody for T cell-mediated diseases.
Cross-linking of P-selectin glycoprotein ligand-1 induces death of activated T cells.
top